Olema Pharmaceuticals announced it will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation at the American Society of Clinical Oncology Annual Meeting taking place May 29-June 2 in Chicago, Illinois. The company will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Oncology announces preclinical data for Palazestrant
- Olema Oncology initiated with a Peer Perform at Wolfe Research
- Olema Oncology assumed with a Buy at Jefferies
- Olema Oncology price target raised to $58 from $55 at JPMorgan
- Olema Oncology price target lowered to $27 from $38 at Goldman Sachs